source
- Tango Therapeutics reports 82% response rate for PRMT5 inhibitor combo in pancreatic cancer trialTango Therapeutics announced a 14% reduction in its workforce while also presenting new data on its PRMT5 inhibitor combined with Revolution Medicines’ RAS(ON) inhibitor Rasonque at the ESMO 2026 m…
- Employers sue UnitedHealth, alleging overpayment of workers' medical claimsSix major U.S. companies have filed a lawsuit against UnitedHealth Group, claiming the insurer overpaid medical claims for their employees, which they say increased their costs. The plaintiffs inc…